Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...

A new mutated variant of Mpox has been identified in Democratic Republic of Congo, with health authorities concerned over ...

ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York underscores the urgent need for a stronger and more diversified vaccine supply chain.

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The mpox virus has mutated, and the new variant, clade 1b, has become more infectious. International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in ...

On August 13, 2024, the Africa Centres for Disease Control and Prevention (Africa CDC) declared the multi-country mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.